Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly

Simon et al. show that the glutaminase GLS1 isoform is augmented in both NASH clinical biopsies and pre-clinical mouse models. GLS1 silencing significantly reduced steatosis and oxidative stress through complex metabolic reprogramming, involving increased VLDL export, indicating that GLS1 may be a valuable therapeutic target for the treatment of NASH.